Chapter 8: Drug Therapy During Pregnancy and Breastfeeding

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

What if I told you that taking asthma medication during pregnancy isn't the real danger, but like stopping that medication actually doubles the risk of stillbirth?

Yeah, it completely inverts how most people think about drug safety, doesn't it?

It really does.

I mean, today we are breaking down the terrifying, high -stakes math of prescribing to pregnant and lactating patients, so welcome to this deep dive.

Thanks for having me.

Whether you are an advanced practice nursing student, a physician assistant student, or just a clinician brushing up on your pharmacology, you are stepping into what might be, well, the most complex landscape in medicine.

Oh, absolutely.

Today's session is drawn strictly from Chapter 8 of Lenny's Pharmacotherapeutics.

And listen, we aren't just going to sit here and memorize lists of bad drugs.

We are going to look at the underlying physiological mechanisms exactly as they unfold in the text so you can build a rock -solid clinical decision -making framework.

And that framework is essential because drug therapy in pregnancy presents a truly vexing dilemma.

You know, in a standard patient, you balance the risks of a treatment against the benefits to that one individual.

Right.

But here, the provider has to balance the risks to the developing fetus against the benefits to the mother.

And you have to do this very often in this fog of incomplete data.

I want to unpack that dilemma right away because the instinct, especially for a newly minted prescriber, is to just go strictly defensive.

You see a pregnant patient, you think, zero drugs.

Let's just stop all medications to protect the baby.

Which is, frankly, an incredibly dangerous instinct.

The text establishes a core clinical priority right from the beginning, which is that the health of the fetus depends entirely on the health of the mother.

Makes sense.

Yeah.

You cannot simply avoid drug therapy when the mother has a condition that threatens her baseline health.

That asthma statistic you opened with is the perfect example from the chapter.

Right.

Because uncontrolled maternal asthma restricts oxygen to the fetus.

Exactly.

The physiological stress of the untreated disease is mathematically far more dangerous than, say, the localized steroids or bronchodilators used to treat it.

Okay.

So you aren't just protecting the fetus from a chemical compound.

You are actively protecting the fetus from the mother's untreated pathophysiology.

Precisely.

So once we accept that drug therapy is often a physiological necessity,

well, we have to understand how to execute it safely.

Yeah.

And that begins with recognizing that a pregnant patient is functioning with a drastically altered pharmacokinetic landscape.

Meaning,

before we even look at what a specific pill does, we really have to look at the environment that pill is entering.

How does the pregnant body physically change the way drugs are absorbed, metabolized, and excreted?

Right.

The chapter looks closely at the kidneys, the liver, and the gastrointestinal tract.

So let's start with the plumbing, basically.

The kidneys.

Okay.

So by the third trimester, a pregnant patient's blood volume has expanded significantly, which means renal blood flow actually doubles.

Wow, doubles.

Yeah, it doubles.

This causes a massive increase in the glomerular filtration rate, or GFR.

So the kidneys are filtering a vastly larger volume of fluid per minute.

So instead of thinking of the kidneys as just like a bouncer kicking drugs out of a club, it's more like someone opened the municipal pressure valves.

That's a good way to put it.

The kidneys are practically power washing the blood, which means any drug eliminated renally is going to be cleared out much faster than normal.

That's a great way to visualize the hemodynamics.

And the clinical consequence is really direct.

You may need to increase the dosage to compensate for that accelerated clearance.

Right.

The text uses the mood stabilizer lithium as an example.

Lithium is a salt.

So the kidneys handle it very similarly to sodium.

During pregnancy, the renal elimination of lithium can increase by 100%.

Wait, 100 %?

Yes.

If you, as the prescriber, don't proactively increase the dose,

the patient's blood levels will plummet below the therapeutic window, risking a severe psychiatric relapse.

OK, so the kidneys are in total overdrive.

What about the liver?

Hepatic metabolism also ramps up for certain drugs.

The text highlights anti -seizure medications specifically.

Phenethorin, carbamazepine, and valproic acid.

The liver enzymes responsible for breaking these down become much more active, so again, the drug is metabolized faster, and you have to monitor blood levels closely to prevent seizure breakthrough.

But then we get to the gastrointestinal tract, and the rules sort of seem to flip.

The chapter notes that the tone and motility of the bowel actually decrease during pregnancy?

Yes, and that's primarily due to elevated levels of circulating progesterone, which relaxes smooth muscle throughout the body, including the intestines.

So this dramatically prolongs intestinal transit time.

OK, wait, let's think about this clinically for a second.

If the GI tract is slowed down like a broken conveyor belt, doesn't that mean drugs just like sit in the intestines longer and get absorbed more into the bloodstream?

Exactly.

Prolonged transit time gives drugs that are normally poorly absorbed a much larger window to just soak into the systemic circulation.

But it also increases something called hepatic recirculation.

I'm glad you brought that up, because that's a dense term.

Let's break that mechanism down for the listener.

What exactly is looping here?

OK, think of it as a recycling loop between the liver and the gut.

Normally the liver processes a drug and dumps the metabolites into the bile, right, which travels to the intestines to be excreted in stool.

Standard process, yeah.

But because the intestinal transit time is so sluggish during pregnancy,

those drugs sit in the gut long enough to be reabsorbed back across the intestinal wall.

Oh, wow.

Yeah, back into the blood and back to the liver.

The drug just keeps taking another lap.

That sounds like a total pharmacokinetic nightmare.

I mean, I'm looking at a patient whose kidneys are flushing drugs out at double speed, but their GI tract is hoarding them and looping them back into the blood.

How do you even dose that?

Well, it requires a highly individualized, really complex balancing act.

For a renally excreted drug, you might increase the dose.

Right.

But for a drug heavily absorbed in the GI tract that undergoes that enterohepatic recirculation, you might actually need to reduce the dosage to prevent toxicity.

So you really can't just rely on standard dosing algorithms.

No, absolutely not.

You have to evaluate the specific pharmacokinetic profile of every single medication.

OK, so we have the mother's altered metabolism mapped out.

But clearing the drug from the maternal system is really only one side of the coin.

What about the fraction of the drug that stays in the blood and reaches the ultimate checkpoint, the placenta?

Yeah, so the placenta is often thought of as a protective shield.

But clinicians need to understand its mechanics.

It's not an absolute barrier.

It follows the exact same biochemical rules as any other cell membrane in the body.

It is a lipid bilayer.

Meaning, like dissolves like.

Exactly.

Lipid -soluble drugs can slip right through the lipid membrane of the placenta pretty easily.

But drugs that are ionized, highly polar, or protein -bound, they bounce off and cross with great difficulty.

Correct.

But the text provides an ultimate clinical safety pearl here that you have to remember.

While the chemistry is true, the clinical reality is far more unpredictable.

For practical purposes, the prescriber must always assume that any drug taken during pregnancy will reach the fetus to some degree.

Assume it all gets through.

Better safe than sorry.

Yes.

But before we look at what the drug does to the fetus, we shouldn't skip over the unique ways these drugs can harm the mother.

The chapter details some very specific pregnancy -related adverse effects.

Right.

For example, heparin, an anticoagulant, is generally safe for the fetus because it doesn't cross the placenta well.

Because it's polar, right?

Yes.

However, in the pregnant mother, long -term use can stimulate osteoclast activity.

Those are the cells that break down bone.

Oh, man.

Yeah, this causes osteoporosis, which can actually lead to spontaneous compression fractures of the spine.

That's terrifying.

A drug you take to prevent blood clots ends up collapsing your vertebrae.

And then there are drugs that mechanically alter the uterus.

Misoprostol is a prime example of that.

It is a synthetic prostaglandin.

And prostaglandins naturally stimulate uterine -smooth muscle.

So taking misoprostol can trigger powerful uterine contractions, leading to a spontaneous abortion.

But on the flip side of that mechanism, the text warns about taking aspirin near term.

Aspirin is a cyclooxygenase inhibitor.

It blocks the production of prostaglandins.

Exactly.

So if a patient takes high doses of aspirin right before delivery, they are chemically suppressing the very contractions needed for labor, while simultaneously increasing the risk for severe maternal bleeding.

It all comes down to understanding the mechanism of action and how it interacts with the physiology of pregnancy.

So let's shift the focus to the newborn for a second.

What happens physiologically when a pregnant patient regularly uses dependence -producing drugs like, you know, heroin, barbiturates, or even alcohol?

Well, the drug crosses the placenta, and the fetus develops a physical dependence right alongside the mother.

Right.

When the infant is born, the umbilical cord is cut, and they are suddenly severed from that drug supply.

Just cut off completely.

Yes.

And the infant's nervous system, which had down -regulated its receptors to adapt to the constant presence of a depressant, well, it suddenly rebounds into severe hyperexcitability.

Which manifests as neonatal withdrawal syndrome.

Clinically, you'll observe a newborn with a high -pitched shrill cry, vomiting, tremors, and extreme irritability.

And you can't just let an infant's nervous system go cold turkey through that kind of shock, right?

Absolutely not.

The physiological stress could be lethal.

The clinical protocol is to gently wean the neonate from dependence by administering progressively smaller doses of the drug, or a substitute drug, carefully tapering them down.

Additionally, clinicians must be hypervigilant about drugs given right at the end of pregnancy.

Maternal pain relievers used during delivery can cross the placenta minutes before birth and depress respiration in the neonate.

Meaning they'd need resuscitation.

Exactly.

Requiring intense monitoring until their breathing normalizes.

So we've seen how drugs can affect the mother and cause withdrawal in the neonate, but now we have to tackle the most feared outcome discussed in Chapter 8, which is teratogenesis.

The word itself comes from the Greek word for monster, literally meaning to produce gross anatomical malformations.

But the real inset from the text isn't just a list of bad chemicals, it's the concept that the timing of the exposure dictates the damage.

Timing is the defining factor in teratogenesis.

But let's look at the baseline data first.

Major structural abnormalities, defects that are life -threatening or require surgery occur in roughly 1 -3 % of all births.

Out of that 1 -3%, how many are actually caused by pharmaceutical drugs?

A surprisingly tiny fraction.

Genetic factors account for about 25 % of all congenital anomalies.

Environmental chemicals and maternal diseases account for others.

But pharmaceutical drugs cause less than 1 % of all birth defects.

Less than 1 %?

That is wild.

I know.

But obviously, since we control the prescription pad, our goal is absolute zero.

So if we look at the timeline of fetal development, the chapter breaks it into three distinct windows of vulnerability.

The first window is the pre -implantation or prezomite period.

This spans from conception through week two.

Prezomite just means it's before the embryo has started forming the structural blocks of tissue that will become the organs.

During this two -week window, teratogens act in an all -or -nothing fashion.

Because the cells are essentially totipotent, right?

Like, they haven't specialized yet.

Exactly.

If the dose is highly toxic, it kills too many cells and causes the death of the conceptus.

Right.

But if the dose is sublethal, the surviving cells can simply compensate, and the conceptus is likely to recover fully with no lasting structural malformations.

Okay, all or nothing in the first two weeks.

Then we hit the critical window.

The embryonic period from weeks three through eight.

This is the stage of organogenesis.

The cells are rapidly differentiating, and the basic shape of the internal organs and limbs is being established.

So this is the danger zone.

Highly dangerous.

If a teratogen disrupts the chemical signaling pathways during this precise window, the result is gross structural malformations.

This is when you see cleft palates, missing limbs, or neural tube defects.

Wow.

And after week eight?

We enter the fetal period, from week nine straight through to term.

Okay.

The organs are mostly formed, so exposure here usually doesn't alter gross anatomy.

Instead, it disrupts growth and function.

The brain is undergoing massive synaptogenesis and wiring during this phase, making it exquivitally vulnerable.

So you're looking at functional deficits.

Exactly.

Exposure during the fetal period leads to learning deficits, behavioral abnormalities, and decreased IQ later in life.

You know, this timeline makes complete sense, but it brings up a really frustrating logistical problem.

We know we can't ethically run clinical trials on pregnant patients.

You can't knowingly give a potential poison to a fetus to see what happens.

Right.

Of course not.

So how do we actually identify a drug as a teratogen?

Why can't we just test them on pregnant mice or rabbits?

Because animal models in teratology are notoriously unreliable.

Teratogenicity is often wildly species -specific.

The metabolic pathways and placental structures are just different.

A drug might cause horrific birth defects in a rat, but be perfectly safe in a human.

Or, much more tragically, a drug can appear completely harmless in an animal but be devastating to a human.

The thalidomide disaster.

Yes, thalidomide is the textbook example of this failure.

It was tested extensively in pregnant laboratory animals and deemed exceptionally safe.

But it wasn't.

No.

When it was prescribed to pregnant humans in the late 1950s for morning sickness.

About 30 % of them had babies with severe, gross malformations like phocomelia.

That's where the long bones of the limbs failed to develop.

Just horrific.

The grim lesson there is that a lack of teratogenicity in animals is absolutely not proof of safety in humans.

And identifying keratogens is even harder because the effects aren't always visible in the delivery room, right?

Yeah, that's the terrifying reality of delayed effects.

The chapter cites diethylstilbistrel, or DES.

It was an estrogenic substance given to prevent miscarriage.

It altered the cellular development in the fetal reproductive tract.

But those changes didn't manifest until puberty -triggered hormonal activation.

It caused a rare form of vaginal cancer in female offspring roughly 18 years after they were born.

18 years later?

I mean, you'd need decades of epidemiological tracking just to connect those dots.

And functional or neurobehavioral effects are even harder to pin down.

If a drug causes a subtle five -point drop in IQ or a learning deficit,

you won't notice it until that child starts the second grade.

Right, how do you prove that?

Proving that deficit was caused by a specific pill the mother took seven years prior is nearly impossible.

But we do have proven examples.

Benzodiazepines taken late in pregnancy can cause central nervous system depression, leading to floppy infant syndrome.

And anti -seizure meds, too, right?

Yes.

Diabol Pro -X is definitively associated with decreased IQ.

So the dangers are profound, and the identification is really difficult.

Let's look at the actual clinical frameworks the chapter provides to help prescribers navigate this.

The text gives us a specific table of proven or strongly suspected teratogens.

Let's look at the mechanisms behind a few of these.

Sure.

Understanding the mechanism really helps you anticipate the defect.

Take tetracyclines, which are antimicrobials.

Their chemical structure causes them to chelate, or bind strongly, to calcium.

During pregnancy, the fetus is rapidly laying down calcium to build bones and teeth.

So the drug binds to that developing tissue.

Exactly, causing permanent tooth discoloration and inhibiting bone growth.

Makes sense based on the chemistry.

What about cardiovascular drugs?

The table mentions ACE inhibitors.

ACE inhibitors block the renin -angiotensin system.

In the second and third trimesters, fetal blood pressure relies heavily on this system, Blocking it causes fetal hypotension and severely decreased renal blood flow, leading to renal failure.

This causes oligohydromyos, a severe lack of amniotic fluid.

And the fluid is protective.

Yes.

Without the cushioning of the amniotic fluid, the fetal skull doesn't develop properly, leading to skull hypoplasia.

That cascade makes total sense.

Now how do we interpret the regulatory guidelines?

Because the text addresses a major shift in how we label drug risks.

Well for decades, the FDA used a simple letter system for pregnancy risk categories A, B, C, D, and X.

Category A meant controlled studies showed no risk, while Category X meant the drug was a known teratogen, the risks clearly outweighed any benefit, and it was strictly contraindicated.

But the FDA phased out those letters.

If they were so simple, why get rid of them?

Because they were dangerously oversimplified.

They implied a linear scale of risk that didn't actually exist, and they didn't provide any context for clinical decision making.

But we still see them in older charts, right?

Yes.

Because this letter system is still heavily present in clinical notes and older literature, students must understand it.

But your primary tool now is the system that replaced it, the Pregnancy and Lactation Labeling Rule, or PLLR.

Okay.

So how does the PLLR structure the information?

It forces you to read the context, right?

Exactly.

It requires three detailed narrative sections in the prescribing information.

The first is pregnancy,

which doesn't just give a letter.

It details available disease registries, summarizes the risks based specifically on human versus animal data, and provides clinical considerations.

Okay.

What's the second section?

The second section is lactation, detailing the amount of drug in human milk and the potential effects on the breastfed infant.

And the third.

The third is females and males of reproductive potential, which spells out specific requirements for pregnancy testing and contraception.

That last section is critical.

What is the clinical protocol if you have a patient of reproductive age who genuinely needs a category X or highly teratogenic drug?

The protocol is proactive counseling.

Roughly 50 % of pregnancies are unintended.

You cannot assume a patient is planning their pregnancies.

Right.

If you prescribe a known teratogen, you must educate the patient about the severe fetal risks and document the absolute necessity of using at least one, if not two, reliable forms of birth control.

But what if the worst happens?

A patient is on a known teratogen, their birth control fails, and they discover they are pregnant.

Say the exposure happens right during weeks three through eight, that critical embryonic period of organogenesis.

What is the actual clinical protocol then?

First, panic helps no one.

You must immediately consult reliable references, like the FDA -approved prescribing information or a teratology database to determine exactly what specific anatomical malformation is associated with that drug.

Okay, gather the facts.

Next, you perform at least two targeted ultrasound scans to physically assess the extent of the injury to the fetus.

Wait, are you saying the clinician and the patient essentially have to make a decision about the continuation of the pregnancy based on those imaging scans?

It is an incredibly difficult situation, but yes.

If the scans reveal a minor or correctable malformation, like a cleft palate, you counsel the patient and prepare for surgical correction after birth.

But if the scans reveal a severe non -viable or life -altering malformation, the clinician must have an honest, evidence -based discussion with the patient regarding the termination of the pregnancy.

Man, it is incredibly heavy, but having that step -by -step, evidence -based protocol is so vital for advanced practice.

Let's transition to the postpartum period.

The baby is born, the delivery is successful, but the sharing of drugs continues through Yes.

Drug therapy during lactation requires us to apply our cell membrane rules one more time.

The epithelial cells of the mammary glands form a lipid bilayer.

So lipid -soluble drugs enter breast milk readily, whereas ionized or highly polar drugs generally do not.

Exactly.

The chapter does note that most drugs enter the milk in concentrations too low to cause clinical harm to the infant.

That is generally true, but prudence and verification are required.

The U .S.

National Library of Medicine maintains a database called LactMed.

Oh, I've heard of that.

It provides free, updated, peer -reviewed data on how drugs affect breastfed infants.

It should really be bookmarked by every prescriber.

The text highlights specific contraindicated drugs versus safe drugs.

Contraindicated means absolutely no breastfeeding.

This includes amphetamines, cocaine, chemotherapy drugs like methotrexate, and radioactive compounds.

Yes, completely off -limits.

But I want to look at the safe list.

It includes acetaminophen, ibuprofen, and penicillins.

But there are two drugs on the safe list that really jump out, warfarin and heparin.

These are powerful blood thinners.

Why wouldn't they cause a nursing baby to bleed out?

It comes right back to the biochemical mechanics.

Let's look at heparin first.

It is an enormous, highly polar polymer.

It physically cannot cross the lipid bilayer of the mammary gland in any meaningful quantity.

Because of its size and charge?

Right.

Furthermore, it's not bioavailable from the GI tract.

So even if a microscopic amount made it into the milk, the infant's stomach would just digest it.

It wouldn't be absorbed systemically.

Okay.

That makes sense.

And warfarin?

Warfarin has a different mechanism of safety.

It is highly protein -bound.

Over 99 % of it binds to albumin in the maternal blood.

Oh, so it gets stuck.

Exactly.

Because it's stuck to these massive maternal proteins, it can't cross into the milk.

Studies show it is completely undetectable in infant plasma.

Structure really does dictate function.

But let's say a nursing mother needs a medication that isn't totally safe, but isn't contraindicated either.

Are there ways to mitigate the exposure without stopping breastfeeding entirely?

Yes.

The text offers clear pharmacokinetic strategies.

First, instruct the patient to take the dose immediately after a breastfeeding session.

Okay.

So you buy some time.

Right.

This ensures the maternal blood concentration, and therefore the milk concentration is at its lowest possible point before the next feeding.

Second, avoid sustained release formulations in drugs with long half -lives.

Because they keep the drug levels constantly elevated in the plasma.

Exactly.

And finally, always use the lowest effective dosage for the shortest possible duration.

That is a brilliant toolkit for minimizing risk.

So to bring this all together,

our goal today wasn't to make you afraid to prescribe.

It was to demonstrate that prescribing for pregnant and nursing patients is about deeply the mechanisms.

Absolutely.

It's knowing why to raise a dose for hyperactive kidneys or lower it for a sluggish GI tract.

It's mastering the developmental timeline so you know exactly when a teratogen will strike and using the PLLR narrative to make informed rather than fearful decisions.

Knowledge, mechanism, and systematic evaluation really must replace fear and guesswork.

I couldn't agree more.

But before we go, I want to leave you with one provocative thought based on the history we impact today.

We discussed how animal testing falsely cleared thalidomide.

And we know that running clinical trials on pregnant humans is inherently unethical.

So going forward in your practice, you really have to ask yourself how many of the newer drugs we currently consider safe or low risk are simply waiting for enough long -term, post -market epidemiological data to prove us wrong.

That is a sobering but profoundly necessary critical perspective for anyone holding a prescription pad.

It really is.

Well, that wraps up our deep dive into Chapter 8.

From everyone here at the Deep Dive and the entire Last Minute Lecture Team, thank you so much for joining us.

Keep asking the hard questions and good luck out there in clinical practice.